Publication trend of TMPRSS2 as SARS-CoV-2 receptor during the COVID-19 pandemic

Irham, Lalu Muhammad and Perwitasari, Dyah Aryani and Nuari, Yudha Rizky and Adikusuma, Wirawan and Firdayani, Firdayani and Dania, Haafizah and Maliza, Rita and Sarasmita, Made Ary and Chong, Rockie and Septama, Abdi Wira (2023) Publication trend of TMPRSS2 as SARS-CoV-2 receptor during the COVID-19 pandemic. Pharmaciana, 13 (1). pp. 58-70. ISSN ISSN:2088-4559,e-ISSN:2477-0256

[thumbnail of 6.Lalu _58-70_Revisi.pdf] Text
6.Lalu _58-70_Revisi.pdf

Download (678kB)


The Coronavirus Disease 2019 (COVID-19) pandemic has not yet been fully under public health control, which is still currently impacting a large number of people worldwide in 2023. Since the pandemic emerged, the growing number of publications related to TMPRSS2 as a SARS-CoV-2 receptor worldwide has increased rapidly with various findings and qualities. It is important to determine the trend of TMPRSS2 publication as no such studies currently exist that represent the publication trend related to this critical field of study. Here, we employed a bibliometric-based approach to evaluate the research trends of TMPRSS2 mechanistically as the SARS-CoV-2 receptor. We identified 1012 research documents published between 2020 and 2022 for this study. The most common document category was "Research Article" (646 articles, 63.84%) followed by "Review Article" (261 articles, 25.79%), and letters to editors (57 articles, 5.63%). Germany was the most cited country with a total of citations (9400 citations), followed by the USA (6409 citations) and China (1788 citations), respectively. In conclusion, given the impact of COVID-19, this study indicated TMPRSS2 as a SARS-CoV-2 receptor as a timely and highly relevant research topic.

Item Type: Artikel Umum
Subjects: R Medicine > RS Pharmacy and materia medica
Divisi / Prodi: Faculty of Pharmacy (Fakultas Farmasi) > S1-Pharmacy (S1-Farmasi)
Depositing User: jurnal pharmaciana
Date Deposited: 15 Apr 2023 03:50
Last Modified: 30 May 2023 08:23

Actions (login required)

View Item View Item